COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31

COLLEGIUM PHARMACEUTICAL, INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$23.01−0.18 (-0.78%)

Close on Oct 19, 2026

Market cap: $746.92M
P/E (TTM): 18.6
Dividend yield: –

COLLEGIUM PHARMACEUTICAL, INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	781	631	567	464	277	310	297	280	28	1.71	–	–	–
Cost of Revenue	317	254	241	254	126	130	194	166	2.60	0.21	–	–	–
Gross Profit	463	377	326	209	151	180	103	115	26	1.50	–	–	–
Research & Development	–	0	0	3.98	9.45	9.77	10	8.66	8.57	15	7.98	15	14
Selling, General & Admin	285	210	159	172	119	114	116	127	93	81	19	2.71	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	19	2.71	1.89
Advertising Expenses	28	11	7.41	–	–	–	–	17	11	16	–	–	–
Operating Expenses	284	207	159	176	133	124	127	135	–	96	27	18	16
Total Costs & Expenses	–	–	–	–	–	–	320	301	104	96	27	–	–
Operating Income	180	170	167	33	18	56	-24	-21	-75	-94	-27	-18	-16
Interest Expense	82	74	83	63	21	29	0.91	20	–	0.09	0.44	0.25	–
Other Non-Operating Income	–	–	–	–	–	–	–	–	0.58	-0.09	-0.35	-0.25	-0.16
Merger & Restructuring Charges	–	–	–	–	4.58	–	–	–	–	–	–	–	–
Pretax Income	93	99	76	-29	-3.37	28	-23	-39	–	–	–	–	–
Income Tax Expense	30	29	28	-3.85	-75	0.83	0	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	63	69	48	-25	72	27	–	–	–	–	–	–	–
Net Income	63	69	48	-25	72	27	-23	-39	-75	-94	-27	-18	-16
EPS (Basic)(per share)	1.98	2.14	1.43	-0.74	2.05	0.78	-0.68	-1.19	-2.47	-3.88	-1.48	-22.72	-4.06
EPS (Diluted)(per share)	1.73	1.86	1.29	-0.74	1.86	0.76	-0.68	-1.19	-2.47	-3.88	-1.48	-22.72	-4.06
Shares Outstanding (Basic, Weighted)(shares)	32	32	34	34	35	34	33	33	30	24	14	0.93	1.70
Shares Outstanding (Diluted, Weighted)(shares)	40	40	42	34	41	35	33	33	30	24	14	0.93	1.70
EBITDA	–	–	–	–	–	–	-23	-20	-75	-93	-27	-17	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 60.0%
Operating margin: 19.5%
Net margin: 5.9%
Return on equity, FY2025: 23.7%

Financial strength

Current ratio: 1.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 21.9%

Valuation

P/E ratio: 18.6
Price to sales: 0.92
Price to book: 2.39
Dividend yield: –